A Phase I/II trial of SCIB2 in combination with a checkpoint inhibitor in patients with solid tumours, focusing on NSCLC in the first instance
Latest Information Update: 24 May 2019
At a glance
- Drugs SCIB 2 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 20 May 2019 According to a Scancell media release, SCIB2 is to be administered using new nanoparticle formulation in this study.
- 14 Dec 2017 According to a Scancell media release, under the terms of the Clinical Development Partnership, Cancer Research UK will fund and sponsor this trial.
- 01 Feb 2017 New trial record